Table of contents


Top

Editorial

Conflicts and collaborations p1133

doi:10.1038/nbt1110-1133

Claims of conflicts of interest concerning authorship of a scientific paper highlight the difficulties facing regulators participating in collaborations with industry.


Top

News

Novartis eyes oral MS drug as potential blockbuster pp1135 - 1136

Mark Ratner

doi:10.1038/nbt1110-1135


Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall pp1137 - 1138

Emma Dorey

doi:10.1038/nbt1110-1137


Shire's replacement enzymes validate gene activation pp1139 - 1140

Nuala Moran

doi:10.1038/nbt1110-1139a


Pharmacogenomics row p1139

Malorye Allison

doi:10.1038/nbt1110-1139b


Joint inspections still cool p1140

Suzanne Elvidge

doi:10.1038/nbt1110-1140a


Stimulus trickle p1140

Nidhi Subbaraman

doi:10.1038/nbt1110-1140b


Transgenic salmon inches toward finish line pp1141 - 1142

Jeffrey L Fox

doi:10.1038/nbt1110-1141a


CIRM spurs translation p1141

Laura DeFrancesco

doi:10.1038/nbt1110-1141b


Irish bait p1141

Christoph Schmitt

doi:10.1038/nbt1110-1141c


Sanofi/Genzyme hostile p1142

Mark Ratner

doi:10.1038/nbt1110-1142a


Adverse-events fraud trial p1142

Michael Francisco

doi:10.1038/nbt1110-1142b


Newsmaker: Anaphore p1143

Jennifer Rohn

doi:10.1038/nbt1110-1143

This protein engineering firm claims its therapies, modeled on the naturally secreted human serum protein tetranectin, could compete with antibodies.


Data Page

Biotech rallies in Q3 p1144

Walter Yang

doi:10.1038/nbt1110-1144


News Feature

When patients march in pp1145 - 1148

Virginia Hughes

doi:10.1038/nbt1110-1145

Impatient with the slow pace of clinical research, families of individuals suffering from untreatable diseases are taking matters into their own hands—with some success. Virginia Hughes reports.


Top

Bioentrepreneur

Building a business

Making the leap into entrepreneurship pp1149 - 1151

Randall Schatzman, Mark Litton, John Latham & Jeffrey Smith

doi:10.1038/bioe.2010.9


Top

Opinion and Comment

Correspondence

Grant management skills are critical for young scientists pp1152 - 1153

Brion Duffy

doi:10.1038/nbt1110-1152


Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins pp1153 - 1156

Carlos J Bosques, Brian E Collins, James W Meador III, Hetal Sarvaiya, Jennifer L Murphy, Guy DelloRusso, Dorota A Bulik, I-Hsuan Hsu, Nathaniel Washburn, Sandra F Sipsey, James R Myette, Rahul Raman, Zachary Shriver, Ram Sasisekharan & Ganesh Venkataraman

doi:10.1038/nbt1110-1153


Commentary

A policy approach to the development of molecular diagnostic tests pp1157 - 1159

Kevin A Schulman & Sean R Tunis

doi:10.1038/nbt1110-1157

Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.


What is the value of oncology medicines? pp1160 - 1163

Joshua Cohen & William Looney

doi:10.1038/nbt1110-1160

Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.


Top

Features

What's fueling the biotech engine—2009–2010 pp1165 - 1171

Saurabh Aggarwal

doi:10.1038/nbt1110-1165

Last year, the biologics sector managed single-digit growth in the United States, driven mainly by products indicated for oncology, diabetes and autoimmune disorders. Lurking on the horizon, though, are challenges, such as pricing, competition and follow-on molecules.


Patents

A shadow falls over gene patents in the United States and Europe pp1172 - 1173

Gareth Morgan & Lisa A. Haile

doi:10.1038/nbt1110-1172

Will a pair of court decisions that restrict the protection offered to DNA-based claims reduce financial incentives and thus chill investment?


Recent patent applications in biological imaging p1174

doi:10.1038/nbt1110-1174


Top

News and Views

Plant natural products from cultured multipotent cells pp1175 - 1176

Susan Roberts & Martin Kolewe

doi:10.1038/nbt1110-1175

Cultured cambial meristematic cells could enable large-scale production of certain natural products.

See also: Research by Lee et al.


Making antibodies from scratch pp1176 - 1178

J Christopher Love

doi:10.1038/nbt1110-1176

Synthesis and screening of a small library of antibody fragments yields promising hits.

See also: Research by Mao et al.


Toward global RNA structure analysis pp1178 - 1179

David M Mauger & Kevin M Weeks

doi:10.1038/nbt1110-1178

Deep sequencing provides a first view of the RNA structures in a eukaryotic transcriptome.


Top

Research Highlights

Research highlights p1180

doi:10.1038/nbt1110-1180


Top

Computational Biology

Commentary

In silico research in the era of cloud computing pp1181 - 1185

Joel T Dudley & Atul J Butte

doi:10.1038/nbt1110-1181

Snapshots of computer systems that are stored and shared 'in the cloud' could make computational analyses more reproducible.


Top

Research

Articles

Directed differentiation of human embryonic stem cells toward chondrocytes pp1187 - 1194

Rachel A Oldershaw, Melissa A Baxter, Emma T Lowe, Nicola Bates, Lisa M Grady, Francesca Soncin, Daniel R Brison, Timothy E Hardingham & Susan J Kimber

doi:10.1038/nbt.1683

Degeneration of articular cartilage in the joints may be amenable to tissue engineering solutions. Oldershaw et al. present an efficient, chemically defined protocol for differentiating human ES cells to chondrocyte-like cells.


Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization pp1195 - 1202

Hongyuan Mao, James J Graziano, Tyson M A Chase, Cornelia A Bentley, Omar A Bazirgan, Neil P Reddy, Byeong Doo Song & Vaughn V Smider

doi:10.1038/nbt.1694

Antibodies that modulate the activity of a target are difficult to discover with display-based approaches, which select only high-affinity binders. Mao et al. identify antibodies with a range of affinities using a small-molecule discovery method that involves one-by-one screening of an optimized small library of antibody fragments with known sequences.

See also: News and Views by Love


Letters

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization pp1203 - 1207

Tomoyuki Igawa, Shinya Ishii, Tatsuhiko Tachibana, Atsuhiko Maeda, Yoshinobu Higuchi, Shin Shimaoka, Chifumi Moriyama, Tomoyuki Watanabe, Ryoko Takubo, Yoshiaki Doi, Tetsuya Wakabayashi, Akira Hayasaka, Shoujiro Kadono, Takuya Miyazaki, Kenta Haraya, Yasuo Sekimori, Tetsuo Kojima, Yoshiaki Nabuchi, Yoshinori Aso, Yoshiki Kawabe & Kunihiro Hattori

doi:10.1038/nbt.1691

The typical therapeutic antibody binds only two target antigen molecules during its lifetime. Igawa et al. describe a method for engineering antibody recycling in vivo, suggesting an approach to reduce the size and/or frequency of dosage with therapeutic antibodies.


Programmable in situ amplification for multiplexed imaging of mRNA expression pp1208 - 1212

Harry M T Choi, Joann Y Chang, Le A Trinh, Jennifer E Padilla, Scott E Fraser & Niles A Pierce

doi:10.1038/nbt.1692

The simultaneous detection of multiple mRNA species in thick tissues or whole-mount embryos has remained technically challenging. Choi et al. present a method based on the triggered polymerization of RNA stem-loop structures that allows the distribution of up to five mRNAs in intact zebrafish embryos to be imaged at the same time.


Cultured cambial meristematic cells as a source of plant natural products pp1213 - 1217

Eun-Kyong Lee, Young-Woo Jin, Joong Hyun Park, Young Mi Yoo, Sun Mi Hong, Rabia Amir, Zejun Yan, Eunjung Kwon, Alistair Elfick, Simon Tomlinson, Florian Halbritter, Thomas Waibel, Byung-Wook Yun & Gary J Loake

doi:10.1038/nbt.1693

The culture of dedifferentiated plant cells to produce commercially important chemicals has met with limited success. Lee et al. demonstrate the potential of innately undifferentiated cells from Taxus cuspidata as an industrial source of the anticancer drug paclitaxel.

See also: News and Views by Roberts & Kolewe


Top

Careers and Recruitment

Third-quarter biotech job picture p1218

Michael Francisco

doi:10.1038/nbt1110-1218


People

People p1220

doi:10.1038/nbt1110-1220


Top